Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1Gynecologic 1

Conditions

Breast Neoplasms 2

Interventions

Paclitaxel 161Fulvestrant 155Trastuzumab 152pembrolizumab 144Letrozole 136Carboplatin 118pertuzumab 104Cyclophosphamide 102Capecitabine 102Specimen Handling 101Anastrozole 90palbociclib 85abemaciclib 81Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 73trastuzumab deruxtecan 69Radiotherapy 61Biopsy 59Surveys and Questionnaires 56Gemcitabine 52130-nm albumin-bound paclitaxel 52sacituzumab govitecan 50olaparib 50Standard of Care 49Blood Specimen Collection 49Taxes 47Doxorubicin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Iohexol × Breast × 1 year × Clear all
NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Stanford University

Phase 1 Terminated
4 enrolled 11 charts
Breast

Breast Neoplasms

NCT05754749 2025-09-25

Comparison of CE-DBT and MRI in Patients With Known Breast Lesions

UNC Lineberger Comprehensive Cancer Center

Phase EARLY_PHASE1 Recruiting
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡